Varda Shoshan-Barmatz | Cancer | Best Researcher Award

Published on by Environmental Scientists

Prof. Varda Shoshan-Barmatz | Cancer | Best Researcher Award

Ben-Gurion University, Life Sciences, Israel

Prof. Varda Shoshan-Barmatz is a renowned Professor of Molecular Physiology at Ben-Gurion University, Israel 🇮🇱. She completed her Ph.D. at the Weizmann Institute and pursued advanced training in the U.S. and Canada 🌎. She served as Director of the National Institute for Biotechnology in Israel (NIBN) from 2006 to 2015. With over 200 publications and 24 patents 🧬, she has been recognized by Forbes and Lady Globes among Israel’s most influential scientists. Her pioneering work focuses on novel therapeutic strategies for cancer and other diseases, influencing both academia and biotech industries 🌟.

Profile

Scopus

Education 🎓

Prof. Shoshan-Barmatz earned her Ph.D. at the prestigious Weizmann Institute of Science in Israel 📘. Further enhancing her expertise, she completed postdoctoral research in leading labs across the United States and Canada 🌎. Her academic journey laid a strong foundation for her breakthroughs in mitochondrial biology and disease therapy 🧪.

Experience 🧑‍🔬

Prof. Shoshan-Barmatz has extensive experience in academia and biotechnology 🏢. She was the founding director of the National Institute for Biotechnology in Israel and has mentored over 100 doctoral and postdoctoral fellows 👩‍🎓👨‍🎓. With involvement in five biotech companies and serving on multiple editorial boards, her leadership spans research, innovation, and entrepreneurship 🚀.

Research Interest 🔬

Her research centers on the mitochondrial protein VDAC1 and its role in diseases such as cancer, diabetes, Alzheimer’s, and metabolic liver diseases 🧬. Prof. Shoshan-Barmatz has innovated several therapeutic strategies by targeting VDAC1 to regulate apoptosis, energy metabolism, and immune responses, shaping the future of personalized medicine 🧠💊.

Awards 🏆

Prof. Shoshan-Barmatz’s groundbreaking contributions have earned her the prestigious Hestrin Prize, the Teva Founders Award, and the Ben-Gurion Award 🏅. She is celebrated as one of Israel’s most influential women in science by Forbes and Lady Globes 🌟, recognizing her impact on biotechnology and molecular research.

Publications 📚

“VDAC1-based peptides: Novel pro-apoptotic agents for cancer therapy” (2020, Cancers) Link here — Cited by 110 articles.

“The mitochondrial voltage-dependent anion channel 1, Ca2+ transport, apoptosis, and their regulation” (2012, Frontiers in Oncology) Link here — Cited by 420 articles.

“VDAC1, a multi-functional mitochondrial protein regulating cell life and death” (2017, Cell Stress) Link here — Cited by 310 articles.

“VDAC1 at the crossroads of cell metabolism, apoptosis and autophagy” (2015, Molecular and Cellular Oncology) Link here — Cited by 150 articles.

Conclusion

Prof. Varda Shoshan-Barmatz is highly suitable for the Best Researcher Award. Her exceptional achievements in research, innovation, mentorship, translational biotechnology, and global scientific leadership make her a distinguished candidate. Her work has had a profound and lasting impact on molecular biology, biotechnology, and medical sciences, fully aligning with the spirit of the award

Mohamed Eltokhy | Cancer Biology | Best Researcher Award

Published on by Environmental Scientists

Mr. Mohamed Eltokhy | Cancer Biology | Best Researcher Award

MSc, TTUHSC, United States

Mohamed Ashraf Eltokhy is a dedicated researcher and Assistant Lecturer at Texas Tech University Health Science Center (TTUHSC) in Abilene, Texas, where he’s contributing to the development of innovative cancer therapies. With an academic background in pharmaceutical sciences, he has experience in both clinical and academic settings, focusing on immunotherapeutic and biotechnological approaches to cancer treatment. Passionate about improving cancer therapies, he leads impactful research initiatives, aiming to advance safer, more effective treatment options for patients.

Profile

Orcid

Google Scholar

Education 🎓

Mohamed holds a Bachelor’s degree in Pharmaceutical Science from Misr International University in Cairo, graduating with high honors (GPA 3.95). He further pursued a Master of Science in Microbiology and Immunology at Al-Azhar University. Currently, he’s a PhD candidate at TTUHSC, studying in the Department of Immunotherapeutic and Biotechnology. His academic journey is marked by consistent excellence and a strong commitment to cancer research, achieving a cGPA of 3.948.

Experience 🧑‍🏫

Mohamed’s diverse experience spans research, academia, and leadership. As the CEO of Neopurpose Therapeutics, he drives strategic decisions, investor relations, and competitor analysis. In academia, he has held positions such as Assistant Lecturer at Misr International University, where he taught microbiology, immunology, and biochemistry. His research experience includes a guest researcher role at Leiden University and involvement in innovative cancer drug studies at TTUHSC, demonstrating his commitment to advancing scientific knowledge and application in cancer therapeutics.

Research Interest 🔬

Mohamed’s research focuses on developing novel anti-cancer agents and bioprinted tumor-on-chip models for drug discovery. His work includes in vitro screening of new compounds, mechanistic studies, and safety evaluations, as well as in vivo research to establish efficacy and safety. His overarching goal is to create more personalized cancer treatment options and to understand the molecular mechanisms involved in cancer progression and treatment.

Awards & Recognition 🏆

Throughout his career, Mohamed has received multiple awards, including the Texas Tech Accelerator Program Award in 2024, and a prestigious poster presentation at the American Association of Cancer Research (AACR). His excellence in academia was recognized with awards for valuable contributions at MIU’s senior conferences and honors for outstanding academic performance in Microbiology and Immunology.

Publications Top Notes 📑

  1. Dec 2021: Eltokhy, M. A., Saad, B. T., Eltayeb, W. N., Yahia, I. S., Aboshanab, K. M., & Ashour, M. S. E. “Exploring the Nature of the Antimicrobial Metabolites Produced by Paenibacillus ehimensis Soil Isolate MZ921932 Using a Metagenomic Nanopore Sequencing Coupled with LC-Mass Analysis,” Journal of Antibiotics (MDPI)..
  2. Nov 2021: Eltokhy, M. A., Saad, B. T., Eltayeb, W. N., El-Ansary, M. R., Aboshanab, K. M., & Ashour, M. S. E. “A metagenomic nanopore sequence analysis combined with conventional screening and spectroscopic methods for deciphering the antimicrobial metabolites produced by Alcaligenes faecalis soil isolate MZ921504,” Journal of Antibiotics (MDPI)..
  3. Sep 2020: Eassa, H. A., Eltokhy, M. A., Fayyaz, H. A., Khalifa, M. K. A., Shawky, S., Helal, N. A., & Nounou, M. I. “Current Topical Strategies for Skin-Aging and Inflammaging Treatment: Science versus Fiction,” Europe PMC..
  4. May 2019: Helal, N. A., Elnoweam, O., Eassa, H. A., Amer, A. M., Eltokhy, M. A., Helal, M. A., Fayyaz, H. A., & Nounou, M. I. “Integrated Continuous Manufacturing in Pharmaceutical Industry: Current Evolutionary Steps Towards Revolutionary Future,” Pharmaceutical Patent Analyst (Clarivate Analytics)..
  5. Jan 2019: Helal, N. A., Eassa, H. A., Amer, A. M., Eltokhy, M. A., Edafiogho, I., & Nounou, M. I. “Nutraceuticals’ novel formulations: the good, the bad, the unknown and patents involved,” Recent Patents on Drug Delivery & Formulation (Bentham Science)..